Malignant vascular tumor

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:673466
Who is this for?
Show terms as
1FDA treatments34Specialists8Treatment centers2Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jul 2026Multiple Myeloma t(4 ;14) FFPE Samples

BIWAKO

TrialNOT YET RECRUITING
Jun 2026Multiple Myeloma Extramedulary Disease Samples FFPE

BIWAKO

TrialNOT YET RECRUITING
Mar 2026Pre-malignant States to Hematologic Malignancies in Firefighters

Wake Forest University Health Sciences

TrialRECRUITING
Dec 2025The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Quercis Pharma AG — PHASE3

TrialRECRUITING
Oct 2025Immune Adverse Events Registry in Onco-Hematologic Patients Treated With Immunotherapy

IRCCS San Raffaele

TrialNOT YET RECRUITING
Sep 2025Latitude - Lateral Lymph Node Attitude Study

Sahlgrenska University Hospital — NA

TrialNOT YET RECRUITING
Jul 2025A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

BioNTech SE — PHASE1, PHASE2

TrialRECRUITING
Jul 2025Improving Diagnosis and Treatment for Patients With Rectal Cancer

Imperial College London — NA

TrialNOT YET RECRUITING
Apr 2025A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

BioNTech SE — PHASE1, PHASE2

TrialRECRUITING
Apr 2025A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma

Peking University First Hospital — EARLY_PHASE1

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Lynparza

olaparib· AstraZeneca Pharmaceuticals LP
for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant,

for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting

No actively recruiting trials found for Malignant vascular tumor at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Malignant vascular tumor community →

Specialists

Showing 25 of 34View all specialists →
GL
Global Clinical Leader
Specialist
PI on 44 active trials4 Malignant vascular tumor publications
NM
Nizar M. Tannir, MD
HOUSTON, TX
Specialist
PI on 3 active trials
BP
BioNTech Responsible Person
Specialist
PI on 18 active trials
DH
David S Hong
Specialist
PI on 7 active trials37 Malignant vascular tumor publications
RM
Robert Maki
PHILADELPHIA, PA
Specialist
PI on 1 active trial6 Malignant vascular tumor publications
FJ
Filip Janku
HOUSTON, TX
Specialist
PI on 4 active trials2 Malignant vascular tumor publications
AM
Aaron S Mansfield
Specialist
PI on 3 active trials3 Malignant vascular tumor publications
RP
Richard Kocharian, MD, PhD
Specialist
PI on 3 active trials
RP
Robert M Prins
Specialist
PI on 1 active trial1 Malignant vascular tumor publication
AM
Amrita Krishnan, MD
DUARTE, CA
Specialist
PI on 2 active trials1 Malignant vascular tumor publication
IP
Irene Franco, PhD
CORPUS CHRISTI, TX
Specialist
PI on 1 active trial
AM
Anissa MEGZARI
Specialist
PI on 15 active trials1 Malignant vascular tumor publication
LM
Lauren Abrey, MD
NEW YORK, NY
Specialist
PI on 1 active trial1 Malignant vascular tumor publication
CM
Catherine Van Poznak, MD
Specialist
PI on 3 active trials
AM
Alessandro Larcher, MD
Specialist
PI on 1 active trial1 Malignant vascular tumor publication
AO
Antonio Omuro
STANFORD, CA
Specialist
PI on 1 active trial
SM
Sjoukje Oosting, MD
Specialist
PI on 2 active trials
JF
James M Ford
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 3 active trials20 Malignant vascular tumor publications
LG
Lilian T Gien
Specialist
PI on 2 active trials1 Malignant vascular tumor publication
YP
Ying Mao, MD, PhD
LEO, IN
Specialist
PI on 1 active trial
RM
Robert McBane
ROCHESTER, MN
Specialist
PI on 1 active trial4 Malignant vascular tumor publications

Treatment Centers

8 centers
⚗️ Trial Site

Children's Hospital of Orange County

📍 Orange, California

👤 Richard Neibeger, MD

⚗️ Trial Site

University of Alabama at Birmingham Cancer Center

📍 Birmingham, Alabama

⚗️ Trial Site

Cedars Sinai Medical Center

📍 Los Angeles, California

👤 Janssen Research & Development, LLC Clinical Trial

⚗️ Trial Site

Kingman Regional Medical Center

📍 Kingman, Arizona

⚗️ Trial Site

Northwestern University

📍 Chicago, Illinois

👤 Ann (Annie) W Silk

⚗️ Trial Site

PCR Oncology

📍 Arroyo Grande, California

⚗️ Trial Site

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

📍 Jonesboro, Arkansas

⚗️ Trial Site

University of South Alabama Mitchell Cancer Institute

📍 Mobile, Alabama

Financial Resources

2 resources
Lynparza(olaparib)AstraZeneca Pharmaceuticals LP

Proleukin

Chiron Corporation

Proleukin — Contact Chiron Corporation

Unverified — confirm before calling
Patient Assistance
Manufacturer Program
Accepting applications

Travel Grants

No travel grants are currently matched to Malignant vascular tumor.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Malignant vascular tumorForum →

No community posts yet. Be the first to share your experience with Malignant vascular tumor.

Start the conversation →

Latest news about Malignant vascular tumor

1 articles
Clinical trialCLINICALTRIALSApr 24, 2026
Trial Now Recruiting: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (NCT06706076)
Researchers are testing a new drug called BH-30643 for advanced lung cancer patients whose tumors have specific genetic mutations (EGFR or HER2). The study will
See all news about Malignant vascular tumor

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Malignant vascular tumor

Which specialists treat Malignant vascular tumor?

25 specialists and care centers treating Malignant vascular tumor are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Malignant vascular tumor?

1 patient support program are currently tracked on UniteRare for Malignant vascular tumor. See the treatments and support programs sections for copay assistance, eligibility, and contact details.